Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

January 31, 2005

Study Completion Date

November 30, 2006

Conditions
Ovarian Neoplasms
Interventions
DRUG

doxorubicin hydrochloride

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY